Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams

Learn more about the current and emerging role of BTK inhibitors in the optimal care of patients with relapsed/refractory MCL, and gain expert insight on personalized approaches to prevent, mitigate and manage the adverse events associated with BTK inhibitors, featuring an on-demand webcast and downloadable slideset from a live workshop series.

Share

Program Content

Activities

Relapsed or Refractory MCL
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 07, 2023

Activities

Advances in MCL
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 10, 2023

Expires: August 09, 2024

Faculty

cover img faculity

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

cover img faculity

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

Jonathon B. Cohen, MD, MS

Co-Director Lymphoma Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Beigene, Ltd. and Lilly.

BeiGene, Ltd.

Lilly